Topic

California

A collection of 516 issues

How to Get Vanflyta (quizartinib) Covered by Cigna in California: Complete Guide with Appeals Process

Quick Answer: Getting Vanflyta Covered by Cigna in California Eligibility: Adults ≥18 with newly diagnosed FLT3-ITD–positive AML. Fastest approval path: Submit prior authorization with confirmed FLT3-ITD lab report, baseline EKG showing QTcF ≤450ms, and treatment plan specifying induction/consolidation/maintenance phases. First step today: Contact your oncologist to order
5 min read

Renewing Filspari (Sparsentan) Coverage with Blue Cross Blue Shield in California: Complete 2024 Guide with Timelines and Forms

Answer Box: Renewing Filspari Coverage in California Blue Shield of California requires quarterly renewal documentation for Filspari (sparsentan), including updated proteinuria labs, liver function tests per REMS requirements, and nephrologist attestation of clinical benefit. Start renewal 30-45 days before expiration. Submit via AuthAccel portal with current UPCR, eGFR, and LFTs.
5 min read

How to Get Entresto (sacubitril/valsartan) Covered by UnitedHealthcare in California: Prior Authorization, Appeals, and Coding Guide

Answer Box: Getting Entresto Covered by UnitedHealthcare in California UnitedHealthcare requires prior authorization for Entresto (sacubitril/valsartan) in California, with approval typically taking 72 hours when proper documentation is submitted. Your fastest path: (1) Have your cardiologist submit a PA through the UHC provider portal with your heart failure diagnosis,
6 min read

How to Get Qinlock (ripretinib) Covered by UnitedHealthcare in California: Forms, Appeals, and Step-by-Step Guide

Answer Box: Getting Qinlock Covered by UnitedHealthcare in California Quick Path to Approval: UnitedHealthcare requires prior authorization for Qinlock (ripretinib) in advanced GIST patients who've failed ≥3 kinase inhibitors including imatinib. Submit through the UnitedHealthcare Provider Portal with documented TKI failure history. If denied, file internal appeal within
5 min read